| NCT ID | NCT02733042 |
| Title | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Celgene Corporation |
| Indications | |
| Therapies |
Durvalumab + Lenalidomide + Rituximab |
| Age Groups: | adult |